Search
forLearn
5 / 801 resultslearn Sildenafil Citrate
learn TRIOXIDIL®
learn tamsulosin
learn Cyproterone
a synthetic anti-androgen and weak progestogen that inhibits DHT binding to androgen receptor
Research
5 / 36 results
research The effect of cilostazol, a phosphodiesterase 3 (PDE3) inhibitor, on human hair growth with the dual promoting mechanisms
Cilostazol helps hair grow by making hair root cells grow faster and changing growth factor levels.
research The effects of phosphodiesterase 3 (PDE3) inhibitor on hair follicle cell viability and hair growth
PDE3 inhibitor may help treat hair loss by promoting hair growth.
research 873 The effect of Cilostazol on hair growth: A novel therapeutic option for the treatment of hair loss
Cilostazol may help hair grow and could be a new treatment for hair loss.
research The Editor's Choice
UV radiation may cause DNA changes in skin, certain UVB therapy helps psoriasis, a new gene mutation is linked to mild piebaldism, different immune cells affect psoriasis, a drug promotes hair growth, and some cancer drugs could treat skin barrier issues.
research Comment on ‘Androgenetic alopecia is associated with increased scalp hardness’: role of phosphodiesterase inhibitors?
Drugs like PDEI may help hair disorders like AGA.
Community Join
5 / 1000+ resultscommunity The no BS guide to saving your hair without finasteride (improvement in 90% of patients in the study) with a low side effect profile or improvement in 100% of patients but a higher side effect profile and increased dosage. The future is here?
Hair loss treatments, specifically the use of oral minoxidil in combination with micro-needling. Oral minoxidil has been found to improve hair density in 90% of patients with a low side effect profile, but using 5mg per day can result in higher side effects including hypertrichosis and edema. Other treatments mentioned include finasteride and RU58841.
community Setipiprant/PGE2 feedbacks?
community What happens if you combine dutasteride and a aromataze inhibitor?
community FCE 28260: A Forgotten 5α-Reductase Inhibitor
FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.
community DLQ01: A Better "Minoxidil" PGF2a synthetic analogue.
DLQ01, a prostaglandin F2α analog, shows promise for hair growth by directly stimulating PGE2/PGF receptors without needing conversion, and can be combined with minoxidil and retinoids like tretinoin for enhanced effectiveness. Minoxidil's efficacy may be reduced by COX-1 inhibitors, but using prostaglandin analogs like Latanoprost or Bimatoprost can help maintain its effectiveness.